Description

Combo Vial: CJC-1295 No DAC/Ipamorelin Kit

 

Save over 55%!

Swipe right to view full table →

 

Peptide Partners Manufacturer Id: WF03

Batch Id: CI20250805

 

Overview

(For educational purposes only)

CJC-1295 represents a significant advancement in peptide therapeutics as a synthetic analog of growth hormone-releasing hormone (GHRH). This peptide has gained attention for its ability to stimulate growth hormone production and release, offering potential benefits for muscle growth, fat loss, and various aspects of metabolic health. Unlike many comparable peptides, CJC-1295’s modified structure provides enhanced stability and an extended half-life, making it particularly interesting for both research and clinical applications.

Molecular Structure and Mechanisms

CJC-1295 is a synthetic heptapeptide consisting of 30 amino acids that functions as a GHRH analog with significant modifications to improve its pharmacokinetic profile.

Structure and Variants

CJC-1295 exists in two primary forms:

·         CJC-1295 without DAC: Has a half-life of approximately 30 minutes

·         CJC-1295 with DAC: Includes a Drug Affinity Complex that allows it to selectively and covalently bind to endogenous albumin after subcutaneous administration, extending its half-life to approximately 6-8 days in humans^[1][2]

The DAC modification represents a significant advancement in peptide design, as it creates a bond with albumin in the bloodstream, dramatically extending the compound’s bioavailability and duration of action. However, some practitioners prefer the non-DAC version as its shorter half-life allows for more predictable dosing schedules^[3].

Physiological Mechanisms

CJC-1295 operates through several key mechanisms:

·         Stimulates the pituitary gland to release growth hormone in a pulsatile pattern, mimicking natural secretion

·         Increases both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in a dose-dependent manner

·         Does not significantly affect other hormone systems, with minimal impact on prolactin, cortisol, acetylcholine, or aldosterone production^[3]

·         May induce proliferation of somatotroph cells in the pituitary, as suggested by increases in total pituitary RNA and GH mRNA in animal studies^[4]

Physiological Effects and Potential Benefits

Research suggests CJC-1295 may offer numerous physiological benefits, primarily stemming from its ability to enhance growth hormone secretion.

Hormone Level Effects

Clinical studies have demonstrated CJC-1295’s significant impact on hormone levels:

·         Single injections produce dose-dependent increases in plasma GH concentrations by 2 to 10-fold, lasting 6 days or longer

·         IGF-1 levels increase by 1.5 to 3-fold for 9-11 days after a single injection

·         After multiple doses, IGF-1 levels can remain elevated for up to 28 days^[5][6]

Reported Therapeutic Benefits

The physiological effects of increased GH and IGF-1 may translate into various health benefits:

·         Musculoskeletal Benefits: Increased muscle mass, improved strength, and enhanced bone density^[2][7]

·         Body Composition Effects: Accelerated fat loss and improved lean body mass ratio^[7][8]

·         Recovery Enhancement: Improved healing from injuries and faster post-exercise recovery^[7][9]

·         Sleep Quality: Promotion of slow-wave deep sleep, which supports muscle growth and memory consolidation^[2]

·         Metabolic Function: Increased protein synthesis and improved metabolic flexibility^[2][7]

·         Skin and Connective Tissue: Increased collagen production potentially benefiting skin elasticity and joint health^[2][9]

·         Cognitive Function: Some reports suggest improvements in cognition and memory^[2][7]

As one source explicitly states: “CJC-1295 offers many benefits to the body, including increased growth hormone secretion and IGF-1 levels with no increase in prolactin, increased protein synthesis, muscle growth, and bone density, improved immune function, cognition, and memory, increased collagen production, fat loss, and cellular repair and regeneration.”^[2]

Clinical Evidence and Research Status

The clinical development of CJC-1295 has progressed through several important studies, though larger-scale investigations are still needed.

Key Clinical Trials

·         Phase I Trials: Two randomized, placebo-controlled, double-blind, ascending dose trials evaluated the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295 in healthy adults aged 21-61^[10][6]

·         Phase II Trial: A 12-week study for CJC-1295 DAC in lipodystrophy involved 192 HIV patients^[5]

·         Animal Studies: Research in GHRH knockout mice demonstrated that daily administration of CJC-1295 normalized body weight, length, and bone growth^[4]

Research Findings

A 2006 study published in the Journal of Clinical Endocrinology & Metabolism found: “Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg. There was evidence of a cumulative effect after multiple doses.”^[6]

In the animal model study: “GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length… Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization.”^[4]

Safety Profile and Considerations

CJC-1295 has demonstrated a generally favorable safety profile in clinical trials, though certain considerations and potential side effects should be noted.

Common Side Effects

The most frequently reported adverse events include:

·         Injection site reactions: transient pain, swelling, and induration, sometimes accompanied by local urticaria^[10]

·         Flu-like symptoms including fatigue and body aches

·         Headache and dizziness

·         Nausea and flushing

·         Joint and muscle pain

·         Rash and edema^[5][3]

Most side effects appear to be mild to moderate and often diminish over time as the body adjusts to treatment.

Safety Considerations

Important considerations regarding CJC-1295 use include:

·         Potential mitogenic effects: Growth hormone may be mitogenic; use with caution in patients prone to cancer or with existing cancer^[5]

·         Thyroid interaction: May mask symptoms of hypothyroidism; thyroid hormone levels should be monitored^[5]

·         Athletic use: CJC-1295 and CJC-1295 with DAC are banned by the World Anti-Doping Agency (WADA) for use in sports^[5]

·         Long-term effects: While short-term safety appears favorable, comprehensive long-term safety data remains limited

Current Applications and Availability

CJC-1295 is available in several contexts, though its regulatory status varies by region.

Medical and Wellness Applications

Current applications of CJC-1295 include:

·         Anti-aging and age-related hormone decline management

·         Body composition optimization (muscle building and fat loss)

·         Performance enhancement and recovery support

·         Sleep quality improvement

·         Potential treatment for specific medical conditions (though research is ongoing)

Availability and Regulatory Status

·         Not FDA approved for any indication in the United States

·         Available primarily as a research compound

·         Used in some wellness and anti-aging clinics, often in combination with other peptides such as Ipamorelin

·         Typically administered as a subcutaneous injection using pre-filled pens or vials

Combination Therapies

CJC-1295 is frequently used in combination with other peptides, particularly Ipamorelin, to enhance therapeutic effects.

CJC-1295 and Ipamorelin

This combination has gained popularity due to complementary mechanisms:

·         CJC-1295 increases the amount of growth hormone released

·         Ipamorelin, a growth hormone secretagogue, amplifies the release frequency

·         Together they create a more steady, sustained release of growth hormone

·         The combination potentially generates 5x the benefits compared to either peptide used individually^[3][11]

Conclusion

CJC-1295 represents a significant advancement in peptide therapeutics for growth hormone modulation. By stimulating the body’s natural production of growth hormone and IGF-1, it offers potential benefits for muscle development, fat metabolism, recovery, and various aspects of physiological function. The DAC modification dramatically extends its half-life, allowing for less frequent dosing compared to other GHRH analogs.

Clinical evidence demonstrates CJC-1295’s ability to substantially increase growth hormone and IGF-1 levels, with a generally favorable safety profile at recommended dosages. However, as with any bioactive compound, careful consideration of individual health factors and appropriate medical supervision are essential.

As research continues to evolve, CJC-1295 may offer promising therapeutic applications for various conditions related to growth hormone deficiency, metabolism, and tissue repair, though further large-scale clinical trials are needed to fully establish its long-term efficacy and safety profile.

⁂

1.       https://en.wikipedia.org/wiki/CJC-1295

2.      https://www.transformyou.com/cjc-1295      

3.      https://www.re-newinstitute.com/content/cjc-1295   

4.      https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006  

5.       https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf     

6.      https://pubmed.ncbi.nlm.nih.gov/16352683/  

7.       https://trtmd.com/cjc-1295-anti-aging-muscle-growth/    

8.      https://oasishealthandmedicine.com/cjc-1295-ipamorelin-the-benefits-of-peptide-therapy/

9.      https://newlifergv.com/cjc-1295-peptide-therapy/ 

10.   https://downloads.regulations.gov/FDA-2024-N-4777-0009/attachment_6.pdf 

https://idahobrainandbody.com/2023/12/22/boosting-wellness-naturally-the-dynamic-duo-of-cjc-1295-and-ipamorelin/